Half-Life & Pharmacokinetics Hub
Concentrations | Timing | Clearance | Research Design
peptide half-life pharmacokinetics research are organized here as a research-use-only reference for comparing mechanisms, quality documentation, batch traceability, and compound selection across OligoPoly Labs research peptides.
Table of Contents
Jump to the comparison tables, compound profiles, quality documentation, FAQ answers, and related OligoPoly research resources.
Compound Pharmacokinetic Profiles
Semaglutide
Type
Long-acting
Approximate t1/2: ~7 days
Tmax: 1-3 days
Route studied: Subcutaneous models
Accumulation: Weekly accumulation
Tirzepatide
Type
Long-acting
Approximate t1/2: ~5 days
Tmax: 1-2 days
Route studied: Subcutaneous models
Accumulation: Weekly accumulation
Retatrutide
Type
Long-acting
Approximate t1/2: ~6 days
Tmax: 1-2 days
Route studied: Subcutaneous models
Accumulation: Weekly accumulation
BPC-157
Type
Short acting
Approximate t1/2: hours
Tmax: Protocol dependent
Route studied: In vitro / model dependent
Accumulation: Minimal
TB-500
Type
Short acting
Approximate t1/2: hours
Tmax: Protocol dependent
Route studied: In vitro / model dependent
Accumulation: Minimal
NAD+
Type
Cellular cofactor
Approximate t1/2: short
Tmax: Rapid
Route studied: Cellular models
Accumulation: Protocol dependent
Ipamorelin
Type
Short acting
Approximate t1/2: ~2 hours
Tmax: rapid
Route studied: GH-axis models
Accumulation: Pulsatile
CJC-1295
Type
Longer acting
Approximate t1/2: days
Tmax: variable
Route studied: GH-axis models
Accumulation: Sustained
Comparative Pharmacokinetic Parameters
| Compound | Type | t1/2 | Tmax | Accumulation | Administration Route | Receptor Affinity Notes |
|---|---|---|---|---|---|---|
| Semaglutide | Long-acting | ~7 days | 1-3 days | Weekly accumulation | Subcutaneous models | Albumin-binding GLP-1 analog |
| Tirzepatide | Long-acting | ~5 days | 1-2 days | Weekly accumulation | Subcutaneous models | Dual GLP-1/GIP pathway |
| Retatrutide | Long-acting | ~6 days | 1-2 days | Weekly accumulation | Subcutaneous models | Triple receptor pathway |
| BPC-157 | Short acting | hours | Protocol dependent | Minimal | In vitro / model dependent | Repair pathway peptide |
| TB-500 | Short acting | hours | Protocol dependent | Minimal | In vitro / model dependent | Actin migration pathway |
| NAD+ | Cellular cofactor | short | Rapid | Protocol dependent | Cellular models | NAD metabolism |
| Ipamorelin | Short acting | ~2 hours | rapid | Pulsatile | GH-axis models | GHSR selectivity |
| CJC-1295 | Longer acting | days | variable | Sustained | GH-axis models | GHRH analog |
Half-Life-Guided Dosing Protocols
Long-Acting GLP
Semaglutide, Tirzepatide, and Retatrutide support weekly exposure-window planning in research models.
Short-Acting Recovery
BPC-157, TB-500, and Ipamorelin require tighter observation and sampling windows.
Ultra-Short Cellular Agents
AOD-9604 and Tesamorelin are often reviewed with short half-life and rapid clearance assumptions.
PK-Guided Research Design
Ready Timeline Planning
Use PK context to define sampling windows, comparison groups, and documentation checkpoints.
PK/PD Correlation Studies
Use PK context to define sampling windows, comparison groups, and documentation checkpoints.
Combination Protocol Design
Use PK context to define sampling windows, comparison groups, and documentation checkpoints.
Bioanalytical Validation
Use PK context to define sampling windows, comparison groups, and documentation checkpoints.
Quality Standards for PK research peptides
OligoPoly Labs aligns research peptide quality standards with batch-specific documentation, HPLC purity context, mass spectrometry confirmation, and online COA access.
HPLC Review
Purity data are reviewed before batch release and connected to lot-level records.
Mass Spec Identity
Identity confirmation supports research suitability and compound traceability.
COA Access
Use COA verification to match a lot number to documentation.
Quality Standards
Review peptide quality standards for handling and documentation details.
Research Citations & External Databases
NIH NLM
NIH National Library of Medicine provides biomedical literature and terminology context for research review.
ClinicalTrials.gov
ClinicalTrials.gov helps researchers review study registrations and public trial context.
Half-Life and Pharmacokinetics Hub FAQs
What is a peptide half-life and why does it matter?
Half-life estimates how long compound concentration remains in a model system. It helps researchers plan timing and sample windows.
How is Tmax different from half-life?
Tmax is the observed time to peak concentration, while half-life describes decline from a concentration point. Both are PK planning concepts.
Why are some peptides short-acting vs long-acting?
Conjugation, sequence structure, binding behavior, and formulation can affect clearance. Compare long-acting GLP compounds with short-acting recovery peptides.
What factors affect peptide bioavailability?
Route, stability, enzymatic degradation, formulation, and model system can affect bioavailability in research settings.
How does PEGylation affect half-life?
PEGylation can increase apparent size and reduce clearance in some compounds, supporting longer exposure windows.
Can peptides with different half-lives be combined?
Combination designs require a clear hypothesis and documentation. Use the compare tool and lot records before designing research.
What happens to peptides after administration in research?
Peptides may distribute, bind, degrade, or clear depending on sequence and model. Researchers should consult literature and study-specific data.
Where can I find full pharmacokinetic data for my compound?
Start with PubMed, product references, and OligoPoly research library resources.